^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | CH4987655 (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
Excerpt:
Evidence of pathway inhibition effects (%pERK) was observed across all cohorts, with strongest effect in patients with BRAF V600-mutant melanoma….PR was achieved in four (23.6%) of 17 patients with BRAF V600-mutant melanoma (Fig. 2A, Table 3), including one receiving study treatment ≥52 weeks (Fig. 3). SD for ≥16 weeks was noted in 5 patients (29%)...In 20 patients with melanomas without BRAF V600 mutation, four (20%) PRs and four (20%) SD were reported (Fig. 2B, Table 3).
DOI:
10.1158/1078-0432.CCR-14-0341
Trial ID:
